Brain, Vol. 122, No. 5, 797-798,
May 1999
© 1999 Oxford University Press
Editorial |
Facts and fallacies on anti-GM1 antibodies: physiology of motor neuropathies
Department of Neurology, Kyoto University Hospital, Kyoto, Japan Professor Emeritus Kyoto University, Kyoto, Japan
Antibodies to ganglioside GM1 (anti-GM1 antibodies) have been implicated in the pathogenesis of GuillainBarré syndrome (GBS), multifocal motor neuropathy (MMN) and motor neuron disease. Although the elevated titres of these antibodies have been amply documented in multifocal motor neuropathy and a motor axonal variant of GBS, or acute motor axonal neuropathy (AMAN), their exact role in the pathogenesis remains elusive. The GM1 epitope is present not only in motor neurons and their axons but also in the dorsal root ganglion cells and sensory axons. If anti-GM1 antibodies are pathogenic, what dictates the predilection for the motor system, and how do these antibodies
References
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. Berciano, A. Garcia, A. Uncini, and M. Capasso Acute motor conduction block neuropathy: Another Guillain-Barre syndrome variant Neurology, March 23, 2004; 62(6): 1026 - 1027. [Full Text] |
||||
![]() |
R. Kaji, H. Bostock, N. Kohara, N. Murase, J. Kimura, and H. Shibasaki Activity-dependent conduction block in multifocal motor neuropathy Brain, August 1, 2000; 123(8): 1602 - 1611. [Abstract] [Full Text] [PDF] |
||||

